Clinical Trial Update: Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating REGN3500 in adults with moderate-to-severe atopic dermatitis has been terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• REGN3500 (anti-IL-33 monoclonal antibody)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Atopic Dermatitis | Phase 2 | Status: TERMINATED | Results posted: 2022-06-10